RHY — Rhythm Biosciences Income Statement
0.000.00%
- AU$26.13m
- AU$25.75m
- AU$3.33m
- 17
- 14
- 35
- 10
Annual income statement for Rhythm Biosciences, fiscal year end - June 30th, AUD millions except per share, conversion factor applied.
2021 June 30th | 2022 June 30th | 2023 June 30th | 2024 June 30th | 2025 June 30th | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | AAS | AAS | AAS | AAS | AAS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 1.12 | 2.44 | 3.31 | 1.74 | 3.33 |
Cost of Revenue | |||||
Gross Profit | -1.07 | 2.24 | 2.75 | -0.896 | -0.347 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 7.73 | 11.2 | 11.5 | 8.6 | 7.09 |
Operating Profit | -6.61 | -8.81 | -8.23 | -6.85 | -3.76 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -6.61 | -8.79 | -8.22 | -6.86 | -3.83 |
Provision for Income Taxes | |||||
Net Income After Taxes | -6.61 | -8.79 | -8.22 | -6.86 | -3.83 |
Net Income Before Extraordinary Items | |||||
Net Income | -6.61 | -8.79 | -8.22 | -6.86 | -3.83 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -6.61 | -8.79 | -8.22 | -6.86 | -3.83 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.035 | -0.041 | -0.037 | -0.017 | -0.014 |